Hib conjugate vaccine

also known as HbOC

Developed for: haemophilus infectious disease
Investigated by: Alaska Native Tribal Health Consortium · Alaska State Public Health Laboratories · CDC-Arctic Investigations Program · Centers for Disease Control and Prevention · Chengdu Olymvax Biopharmaceuticals Inc. · Jiangsu Province Centers for Disease Control and Prevention
+3 more
· National Institute of Allergy and Infectious Diseases (NIAID) · Public Health England · Yukon Kuskokwim Health Corporation

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 31 trial
Phase 3	NCT02692859	Sep 2013 → Aug 2014	haemophilus infectious disease	Jiangsu Province Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 42 trials
Phase 4	NCT00197782	Apr 2003 → Dec 2005	haemophilus infectious disease	Public Health England	Completed	No outcome recorded
Phase 4	NCT00153556	Sep 2001 → Nov 2003	haemophilus infectious disease	Centers for Disease Control and Prevention	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Hib conjugate vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02692859 ↗ 2 NCT00197782 ↗ NCT00153556 ↗
Known as	HbOC	“Hib conjugate vaccine (HbOC, Wyeth Vaccines)” NCT00153556 ↗
Modality	Vaccine	“Hib conjugate vaccine (HbOC, Wyeth Vaccines)” NCT00153556 ↗